ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación ...
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
[9],[10] Commenting on World Diabetes Day 2024, Mr. Satyaprakash Tiwari, Executive Director at Diabetes Singapore ... General Manager of GSK Singapore. Since its inception in 1971, Diabetes Singapore ...
Explore first person business intelligence from top minds curated for a global executive audience The 16th edition of the ...
There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...
With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
Ms. Koehler succeeds Ranndy Kellogg, takes the helm of the U.S. and Canada's leading brand of personal heart health products ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback